Dublin, May 22, 2017 -- Research and Markets has announced the addition of the "Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine Brands Analysis" report to their offering.
Global Influenza Vaccine Market is worth more than US$ 5 Billion
Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine Brands Analysis is our 8th report on the Influenza Vaccine Market. This is a 383 page report with 386 Figures and 7 Tables provides data of 30 countries globally on Influenza Vaccine Market. The report provides data on Pediatrics and Adult Influenza Vaccinated Population Numbers and Market.
Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.
United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022.
Scope of Study:
- Influenza Vaccine Market has been divided into two segments Pediatrics Influenza Vaccine Market and Adult Influenza Vaccine Market
- Influenza Vaccine Market share & Forecast, Pediatrics Influenza Vaccine Market share & Forecast and Adult Influenza Vaccine Market share & Forecast
- Influenza Vaccinated Population & Forecast has been divided into two segments Pediatrics Influenza Vaccinated Population & Forecast and Adult Influenza Vaccinated Population & Forecast
- Influenza Vaccine Brand Sales and Forecast
All 30 Countries have been extensively studied from 2 major points, which has been further sub-divided into 2 more points:
1. Influenza Vaccine Market & Forecast (2011 - 2022)
a. Pediatrics Influenza Vaccine Market & Forecast
b. Adult Influenza Vaccine Market & Forecast
2. Influenza Vaccinated Population & Forecast (2011 - 2022)
a. Pediatrics Influenza Vaccinated Population & Forecast
b. Adult Influenza Vaccinated Population & Forecast
This report offers the best viewpoint on the leading five influenza vaccine brands:
1. Vaxigrip/Fluzone
2. Fluarix/ Flulaval
3. FluMist/Fluenz
4. Afluria/Fluvax and Fluvirin/Flucelvax
5. Anflu
This report is a combination of 6 reports:
1. Europe Influenza Vaccine Market & Forecast (23 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine Brands Analysis
2. Influenza Vaccine Market in Italy, Malta, Portugal and Spain (South Europe) By (Child & Adult) Forecast
3. Influenza Vaccine Market & Forecast in (West Europe) Netherlands, Germany, France, Ireland, Luxembourg, Poland and United Kingdom By (Child & Adult)
4. Nordics Seasonal Influenza Vaccine Market Forecast in (Denmark, Finland, Iceland, Norway & Sweden) By (Child & Adult) Vaccination
5. Seasonal Influenza Vaccination Market in Hungary, Romania, Slovakia and Slovenia (East Europe) By (Infant & Adult) Forecast
6. Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast
Key Topics Covered:
1 Executive Summary
2 Influenza - Introduction
3 Structure of Influenza Virus
4 Notable Influenza Pandemics
5 Worldwide Influenza Vaccinated Population
6 Worldwide Seasonal Influenza Vaccine Market
7 Worldwide Seasonal Influenza Vaccine Market Share Analysis
8 United States
9 Netherlands
10 Denmark
11 Estonia
12 Finland
13 Germany
14 France
15 Hungary
16 Iceland
17 Ireland
18 Italy
19 Latvia
20 Lithuania
21 Luxembourg
22 Malta
23 Norway
24 Poland
25 Portugal
26 Romania
27 Slovakia
28 Slovenia
29 Spain
30 Sweden
31 United Kingdom
32 China
33 India
34 Brazil
35 Japan
36 Australia
37 New Zealand
38 Worldwide - Seasonal Influenza Vaccine Brand Sales and Forecast
39 Seasonal Influenza Vaccine - Growth Drivers
40 Seasonal Influenza Vaccine - Challenges
For more information about this report visit http://www.researchandmarkets.com/research/5tq8d8/global_influenza
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines, Pediatrics


Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals
The Maire - EuroChem Case: Three Lessons for Global Business
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership
ASML’s EUV Monopoly Powers the Global AI Chip Boom
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 



